Breaking Barriers in Cancer Treatment: Halda Therapeutics Secures $126M in Series B Funding for Revolutionary Precision Medicines

Halda Therapeutics is thrilled to announce the successful closure of a $126 million funding round, a significant leap forward in our mission to revolutionize cancer treatment through innovative precision medicines. Founded by esteemed Yale scientist, Professor Craig Crews, Halda is at the forefront of biotechnology, dedicated to our pioneering RIPTAC™ therapeutics—a cutting-edge drug modality that effectively addresses cancer without depending on traditional oncogenic disease drivers. Our novel approach comes in response to the urgent need for solutions to drug-resistant cancers, employing a groundbreaking ‘hold and kill’ mechanism that selectively targets cancer cells by assembling two proteins in a tightly controlled manner. This interaction leads to a critical loss of survival function in malignant cells, inducing cell death and holding great promise for patients facing limited treatment options. The substantial funding raised will not only support the development of our existing pipeline of RIPTAC therapeutics but also fuel our continued innovation to create new medicine via our proprietary platform technology. Operating from our state-of-the-art facilities in Science Park, New Haven, CT, we are proud to harness an environment where collaboration, passion, and creativity flourish. This funding is a testament to our commitment to push the boundaries of drug discovery, enabling us to confront and ultimately conquer some of the most challenging aspects of cancer treatment. We are excited about the journey ahead and the potential impact our work will have on the lives of patients battling cancers marked by drug resistance.